Abstract
Aim: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. Patients & methods: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. Results: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. Conclusion: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.
| Original language | English |
|---|---|
| Pages (from-to) | 443-448 |
| Number of pages | 6 |
| Journal | Future Oncology |
| Volume | 14 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Feb 1 2018 |
Fingerprint
Keywords
- abiraterone acetate
- cardiovascular risk factors
- frail patients
- metastatic castration-resistant prostate cancer
- multidisciplinary management
- prospective study
- safety
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients : A prospective evaluation. / Prati, Veronica; Ruatta, Fiorella; Aversa, Caterina; Gernone, Angela; Galizia, Danilo; Bonzano, Alessandro; Torino, Sofia; Nuzzolese, Imperia; Marandino, Laura; Aglietta, Massimo; Ortega, Cinzia.
In: Future Oncology, Vol. 14, No. 5, 01.02.2018, p. 443-448.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients
T2 - A prospective evaluation
AU - Prati, Veronica
AU - Ruatta, Fiorella
AU - Aversa, Caterina
AU - Gernone, Angela
AU - Galizia, Danilo
AU - Bonzano, Alessandro
AU - Torino, Sofia
AU - Nuzzolese, Imperia
AU - Marandino, Laura
AU - Aglietta, Massimo
AU - Ortega, Cinzia
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Aim: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. Patients & methods: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. Results: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. Conclusion: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.
AB - Aim: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. Patients & methods: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. Results: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. Conclusion: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.
KW - abiraterone acetate
KW - cardiovascular risk factors
KW - frail patients
KW - metastatic castration-resistant prostate cancer
KW - multidisciplinary management
KW - prospective study
KW - safety
UR - http://www.scopus.com/inward/record.url?scp=85041571120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041571120&partnerID=8YFLogxK
U2 - 10.2217/fon-2017-0385
DO - 10.2217/fon-2017-0385
M3 - Article
C2 - 29318908
AN - SCOPUS:85041571120
VL - 14
SP - 443
EP - 448
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 5
ER -